The "Making Insulin Affordable for All Children Act" caps insulin costs for those 26 and under on private health insurance plans at $35 per month, beginning in 2026.
Greg Landsman
Representative
OH-1
The "Making Insulin Affordable for All Children Act" aims to lower insulin costs for individuals aged 26 and under with private health insurance. Beginning in 2026, private health plans must cover selected insulin products without a deductible and cap the cost-sharing at $35 per 30-day supply or 25% of the negotiated price, whichever is lower. This ensures that young people have affordable access to this life-saving medication.
This proposed legislation, the "Making Insulin Affordable for All Children Act," aims to put a ceiling on insulin costs for younger individuals covered by private health insurance. Starting in 2026, the bill mandates that these plans limit out-of-pocket expenses for insulin to $35 per month or 25% of the plan's negotiated price, whichever is less. Critically, this cap applies before the deductible is met for certain insulin products.
The core idea here is straightforward: make insulin more predictable and affordable for people 26 and under. Section 2 of the bill prevents private health plans from making you pay your full deductible before covering insulin. Instead, your monthly cost for a 30-day supply would be capped at the lower of $35 or a quarter of the price your insurer negotiated (after discounts). Think of a recent grad managing diabetes while starting their first job – instead of potentially facing hundreds upfront for insulin, their cost for covered types would be predictable and significantly lower, right from the start of the plan year.
Here's where it gets a bit more nuanced. The $35 cap doesn't automatically apply to every insulin product on the market. The bill requires plans to cover at least one version of each type (like rapid-acting, long-acting) and dosage form (like vials, pens) without a deductible and subject to the cap. However, the specific brands or products that get this treatment are chosen by the health plan itself. This means while access should improve, you might need to use the specific insulin product your plan selects to get the maximum cost savings, which might not be the one your doctor initially prescribed or the one that works best for you. It’s a trade-off between guaranteed lower costs for some options versus potentially limited choice.
This change isn't immediate. The provisions are set to kick in for plan years beginning on or after January 1, 2026. The responsibility for making sure this actually happens falls to the big federal agencies overseeing health (HHS), labor (DOL), and taxes (Treasury). They'll be the ones writing the specific rules and ensuring insurance companies comply. So, while the bill sets the target, the real-world implementation details will depend on how these agencies interpret and enforce the law over the next couple of years.